Marinobufagenin, left ventricular geometry and cardiac dysfunction in end-stage kidney disease patients.
End-stage kidney disease
Hemodialysis
Left-ventricular hypertrophy
Marinobufagenin
Peritoneal dialysis
Uremic cardiomyopathy
Journal
International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
08
10
2021
accepted:
23
02
2022
pubmed:
12
3
2022
medline:
14
9
2022
entrez:
11
3
2022
Statut:
ppublish
Résumé
Left ventricular hypertrophy (LVH) is remarkably prevalent among end-stage kidney disease (ESKD) on chronic dialysis and has a strong prognostic value for adverse outcomes. In experimental models, the endogenous cardiotonic steroid Marinobufagenin (MBG) promotes cardiac hypertrophy and accelerates uremic cardiomyopathy. In this study, we investigated the possible relationships between MBG, LV geometry and cardiac dysfunction in a clinical setting of ESKD. Plasmatic MBG was measured in 46 prevalent ESKD patients (n = 30 HD, n = 16 PD) together with a thorough laboratory, clinical, bioimpedance and echocardiography assessment. Different patterns of LV geometry were defined by left ventricular mass index (LVMi) and ventricular morphology. Diastolic dysfunction was diagnosed by the ASE/EACVI criteria. MBG levels were significantly higher in ESKD patients than in healthy controls (p = 0.001) and more elevated in PD than in HD (p = 0.02). At multivariate analyses, E/e' (β = 0.38; p = 0.009) and LVMi (β = 0.42; p = 0.02) remained the sole independent predictors of MBG. A statistically significant trend in MBG levels (p = 0.01) was noticed across different patterns of LV geometry, with the highest values found in eccentric LVH. MBG levels were higher in the presence of diastolic dysfunction (p = 0.01) and this substance displayed a remarkable diagnostic capacity in distinguish patients with normal LV geometry, LV hypertrophy and, particularly, eccentric LVH (AUC 0.888; p < 0.0001) and diastolic dysfunction (AUC 0.79; p = 0.001). Deranged plasma MBG levels in ESKD patients on chronic dialysis reflect alterations in LV structure and function. MBG may, thus, candidate as a novel biomarker for improving cardiac assessment in this high-risk population.
Identifiants
pubmed: 35274285
doi: 10.1007/s11255-022-03161-0
pii: 10.1007/s11255-022-03161-0
doi:
Substances chimiques
Bufanolides
0
marinobufagenin
3KBT25GV2B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2581-2589Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
de Albuquerque Suassuna PG, Sanders-Pinheiro H, de Paula RB (2018) Uremic cardiomyopathy: a new piece in the chronic kidney disease-mineral and bone disorder puzzle. Front Med (Lausanne) 5:206
doi: 10.3389/fmed.2018.00206
Zoccali C, Benedetto FA, Mallamaci F et al (2004) Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65(4):1492–1498
doi: 10.1111/j.1523-1755.2004.00530.x
Parfrey PS, Harnett JD, Griffiths SM et al (1990) The clinical course of left ventricular hypertrophy in dialysis patients. Nephron 55(2):114–120
doi: 10.1159/000185937
Garikapati K, Goh D, Khanna S et al (2021) Uraemic cardiomyopathy: a review of current literature. Clin Med Insights Cardiol 15:1179546821998347
doi: 10.1177/1179546821998347
Schoner W, Scheiner-Bobis G (2007) Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293(2):C509-536
doi: 10.1152/ajpcell.00098.2007
Haas M, Askari A, Xie Z (2000) Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase. J Biol Chem 275(36):27832–27837
doi: 10.1074/jbc.M002951200
Bagrov AY, Shapiro JI, Fedorova OV (2009) Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 61(1):9–38
doi: 10.1124/pr.108.000711
Kometiani P, Li J, Gnudi L et al (1998) Multiple signal transduction pathways link Na+/K+-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J Biol Chem 273(24):15249–15256
doi: 10.1074/jbc.273.24.15249
Xie Z, Kometiani P, Liu J et al (1999) Intracellular reactive oxygen species mediate the linkage of Na+/K+-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem 274(27):19323–19328
doi: 10.1074/jbc.274.27.19323
Kennedy DJ, Vetteth S, Periyasamy SM et al (2006) Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy. Hypertension 47(3):488–495
doi: 10.1161/01.HYP.0000202594.82271.92
Pavlovic D (2020) Endogenous cardiotonic steroids and cardiovascular disease, where to next? Cell Calcium 86:102156
doi: 10.1016/j.ceca.2019.102156
Keppel MH, Piecha G, Marz W et al (2019) The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension. PLoS ONE 14(2):e0212973
doi: 10.1371/journal.pone.0212973
Slabiak-Blaz N, Piecha G (2021) Endogenous mammalian cardiotonic steroids-a new cardiovascular risk factor? A mini-review. Life (Basel) 11(8):727
Bolignano D, Greco M, Presta P et al (2021) Altered circulating marinobufagenin levels and recurrent intradialytic hypotensive episodes in chronic hemodialysis patients: a pilot, prospective study. Rev Cardiovasc Med 22(4):1577–1587
doi: 10.31083/j.rcm2204163
Piecha G, Kujawa-Szewieczek A, Kuczera P et al (2018) Plasma marinobufagenin immunoreactivity in patients with chronic kidney disease: a case control study. Am J Physiol Renal Physiol 315(3):F637–F643
doi: 10.1152/ajprenal.00046.2018
Lang RM, Badano LP, Mor-Avi V et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270
doi: 10.1093/ehjci/jev014
Moreno FL, Hagan AD, Holmen JR et al (1984) Evaluation of size and dynamics of the inferior vena cava as an index of right-sided cardiac function. Am J Cardiol 53(4):579–585
doi: 10.1016/0002-9149(84)90034-1
Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 17(12):1321–1360
doi: 10.1093/ehjci/jew082
Galie N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37(1):67–119
doi: 10.1093/eurheartj/ehv317
Marwick TH, Gillebert TC, Aurigemma G et al (2015) Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). J Am Soc Echocardiogr 28(7):727–754
doi: 10.1016/j.echo.2015.05.002
Nagueh SF, Smiseth OA, Appleton CP et al (2016) Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29(4):277–314
doi: 10.1016/j.echo.2016.01.011
Manunta P, Hamilton BP, Hamlyn JM (2006) Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 290(3):R553-559
doi: 10.1152/ajpregu.00648.2005
Strauss M, Smith W, Kruger R et al (2018) Marinobufagenin and left ventricular mass in young adults: The African-PREDICT study. Eur J Prev Cardiol 25(15):1587–1595
doi: 10.1177/2047487318788140
Strauss-Kruger M, Kruger R, Smith W et al (2020) The cardiotonic steroid marinobufagenin is a predictor of increased left ventricular mass in obesity: the African-PREDICT study. Nutrients 12(10):3185
doi: 10.3390/nu12103185
Kennedy DJ, Shrestha K, Sheehey B et al (2015) Elevated plasma marinobufagenin, an endogenous cardiotonic steroid, is associated with right ventricular dysfunction and nitrative stress in heart failure. Circ Heart Fail 8(6):1068–1076
doi: 10.1161/CIRCHEARTFAILURE.114.001976
Fridman AI, Matveev SA, Agalakova NI et al (2002) Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity. J Hypertens 20(6):1189–1194
doi: 10.1097/00004872-200206000-00032
Liu C, Bai Y, Chen Y et al (2012) Reduction of Na/K-ATPase potentiates marinobufagenin-induced cardiac dysfunction and myocyte apoptosis. J Biol Chem 287(20):16390–16398
doi: 10.1074/jbc.M111.304451
Stella P, Manunta P, Mallamaci F et al (2008) Endogenous ouabain and cardiomyopathy in dialysis patients. J Intern Med 263(3):274–280
doi: 10.1111/j.1365-2796.2007.01883.x
Pitzalis MV, Hamlyn JM, Messaggio E et al (2006) Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur J Heart Fail 8(2):179–186
doi: 10.1016/j.ejheart.2005.07.010
de Roij van Zuijdewijn CL, Hansildaar R, Bots ML et al (2015) Eccentric left ventricular hypertrophy and sudden death in patients with end-stage kidney disease. Am J Nephrol 42(2):126–133
doi: 10.1159/000439447